<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35535655</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1478-3231</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
          <ISOAbbreviation>Liver Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact on follow-up strategies in patients with primary sclerosing cholangitis.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.15286</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Liver International published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bergquist</LastName>
            <ForeName>Annika</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3858-6241</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weismüller</LastName>
            <ForeName>Tobias J</ForeName>
            <Initials>TJ</Initials>
            <Identifier Source="ORCID">0000-0001-9736-1483</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levy</LastName>
            <ForeName>Cynthia</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-5498-6037</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Digestive Health and Liver Diseases, University of Miami, Florida, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Schiff Center for Liver Diseases, University of Miami, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rupp</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Infectious Diseases, Intoxication, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joshi</LastName>
            <ForeName>Deepak</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Liver Studies, King's College Hospital, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nayagam</LastName>
            <ForeName>Jeremy Shanika</ForeName>
            <Initials>JS</Initials>
            <Identifier Source="ORCID">0000-0002-0344-0218</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Liver Studies, King's College Hospital, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montano-Loza</LastName>
            <ForeName>Aldo J</ForeName>
            <Initials>AJ</Initials>
            <Identifier Source="ORCID">0000-0002-2511-7980</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Liver Unit, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lytvyak</LastName>
            <ForeName>Ellina</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Liver Unit, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wunsch</LastName>
            <ForeName>Ewa</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0001-8740-5243</Identifier>
            <AffiliationInfo>
              <Affiliation>Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Milkiewicz</LastName>
            <ForeName>Piotr</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-1817-0724</Identifier>
            <AffiliationInfo>
              <Affiliation>Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zenouzi</LastName>
            <ForeName>Roman</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schramm</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cazzagon</LastName>
            <ForeName>Nora</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network on Hepatological Disease, European Reference Network for Hepatological Diseases, Azienda Ospedaliera-Università di Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Floreani</LastName>
            <ForeName>Annarosa</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Studiosa Senior University of Padova, Italy and Scientific Consultant IRCCS Negrar, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liby</LastName>
            <ForeName>Ingalill Friis</ForeName>
            <Initials>IF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiestler</LastName>
            <ForeName>Miriam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wedemeyer</LastName>
            <ForeName>Heiner</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-2906-0480</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Taotao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strassburg</LastName>
            <ForeName>Christian P</ForeName>
            <Initials>CP</Initials>
            <Identifier Source="ORCID">0000-0001-7870-5359</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rigopoulou</LastName>
            <ForeName>Eirini</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-1978-4602</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dalekos</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Narasimman</LastName>
            <ForeName>Manasa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Schiff Center for Liver Diseases, University of Miami, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verhelst</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ghent Liver Research Center, Ghent University, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Degroote</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ghent Liver Research Center, Ghent University, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vesterhus</LastName>
            <ForeName>Mette</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Norwegian PSC Research Centre, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kremer</LastName>
            <ForeName>Andreas E</ForeName>
            <Initials>AE</Initials>
            <Identifier Source="ORCID">0000-0002-9263-948X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bündgens</LastName>
            <ForeName>Bennet</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rorsman</LastName>
            <ForeName>Fredrik</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, University Hospital, Uppsala, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nilsson</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Gastroenterology Clinic, Skåne University Hospital, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jørgensen</LastName>
            <ForeName>Kristin Kaasen</ForeName>
            <Initials>KK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>von Seth</LastName>
            <ForeName>Erik</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-6976-248X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cornillet Jeannin</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-7981-0927</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nyhlin</LastName>
            <ForeName>Nils</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>Harry</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, University College Hospitals NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kechagias</LastName>
            <ForeName>Stergios</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-7614-739X</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit of Internal Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiencke</LastName>
            <ForeName>Kristine</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Norwegian PSC Research Centre, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Werner</LastName>
            <ForeName>Mårten</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beretta-Piccoli</LastName>
            <ForeName>Benedetta Terziroli</ForeName>
            <Initials>BT</Initials>
            <Identifier Source="ORCID">0000-0001-5004-5029</Identifier>
            <AffiliationInfo>
              <Affiliation>Epatocentro Ticino, Università della Svizzera Italiana, Lugano, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marzioni</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-6014-6165</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti - University Hospital, Ancona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Isoniemi</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Transplantation and Liver Surgery, Abdominal Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arola</LastName>
            <ForeName>Johanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Huslab, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wefer</LastName>
            <ForeName>Agnes</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Surgery, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Söderling</LastName>
            <ForeName>Jonas</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Färkkilä</LastName>
            <ForeName>Martti</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-0250-8559</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinic of Gastroenterology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lenzen</LastName>
            <ForeName>Henrike</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-0903-1415</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>European Reference Network for Hepatological Diseases, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>International PSC Study Group</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Liver Int</MedlineTA>
        <NlmUniqueID>101160857</NlmUniqueID>
        <ISSNLinking>1478-3223</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ERCP</Keyword>
        <Keyword MajorTopicYN="N">MRI</Keyword>
        <Keyword MajorTopicYN="N">cholangiocarcinoma</Keyword>
        <Keyword MajorTopicYN="N">follow-up strategy</Keyword>
        <Keyword MajorTopicYN="N">primary sclerosing cholangitis</Keyword>
        <Keyword MajorTopicYN="N">surveillance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35535655</ArticleId>
        <ArticleId IdType="doi">10.1111/liv.15286</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045-2055.</Citation>
        </Reference>
        <Reference>
          <Citation>Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321-327.</Citation>
        </Reference>
        <Reference>
          <Citation>Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152(8):1975-84 e8.</Citation>
        </Reference>
        <Reference>
          <Citation>Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol. 2010;34(1):27-34.</Citation>
        </Reference>
        <Reference>
          <Citation>Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48(4):1106-1117.</Citation>
        </Reference>
        <Reference>
          <Citation>von Seth E, Arnelo U, Enochsson L, Bergquist A. Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography. Liver Int. 2015;35(1):254-262.</Citation>
        </Reference>
        <Reference>
          <Citation>Rupp C, Hippchen T, Bruckner T, et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut. 2019;68(12):2170-2178.</Citation>
        </Reference>
        <Reference>
          <Citation>Bowlus CL, Lim JK, Lindor KD. AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: expert review. Clin Gastroenterol Hepatol. 2019;17(12):2416-2422.</Citation>
        </Reference>
        <Reference>
          <Citation>Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356-1378.</Citation>
        </Reference>
        <Reference>
          <Citation>Ali AH, Tabibian JH, Nasser-Ghodsi N, et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology. 2018;67(6):2338-2351.</Citation>
        </Reference>
        <Reference>
          <Citation>Trivedi PJ, Crothers H, Mytton J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020;159(3):915-928.</Citation>
        </Reference>
        <Reference>
          <Citation>Eaton JE, Welle CL, Bakhshi Z, et al. Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis. Hepatology. 2020;73:1868-1881.</Citation>
        </Reference>
        <Reference>
          <Citation>Boyd S, Mustonen H, Tenca A, Jokelainen K, Arola J, Farkkila MA. Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. Scand J Gastroenterol. 2017;52(2):242-249.</Citation>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267.</Citation>
        </Reference>
        <Reference>
          <Citation>Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660-678.</Citation>
        </Reference>
        <Reference>
          <Citation>Aabakken L, Karlsen TH, Albert J, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the liver (EASL) clinical guideline. Endoscopy. 2017;49(6):588-608.</Citation>
        </Reference>
        <Reference>
          <Citation>Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54(5):1842-1852.</Citation>
        </Reference>
        <Reference>
          <Citation>Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J, IPSCSG MRIwgot. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the international PSC study group. Hepatology. 2017;66(5):1675-1688.</Citation>
        </Reference>
        <Reference>
          <Citation>Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50(9):1734-1740.</Citation>
        </Reference>
        <Reference>
          <Citation>Wannhoff A, Rupp C, Friedrich K, et al. Inflammation but not biliary obstruction is associated with carbohydrate antigen 19-9 levels in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2015;13(13):2372-2379.</Citation>
        </Reference>
        <Reference>
          <Citation>von Seth E, Ouchterlony H, Dobra K, et al. Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver Int. 2018;39:382-388.</Citation>
        </Reference>
        <Reference>
          <Citation>Singhi AD, Nikiforova MN, Chennat J, et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut. 2020;69(1):52-61.</Citation>
        </Reference>
        <Reference>
          <Citation>Han S, Kahaleh M, Sharaiah RZ, et al. Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial. Gastrointest Endosc. 2021;94:569-576.e1.</Citation>
        </Reference>
        <Reference>
          <Citation>Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015;81(1):168-176.</Citation>
        </Reference>
        <Reference>
          <Citation>Nguyen NQ, Schoeman MN, Ruszkiewicz A. Clinical utility of EUS before cholangioscopy in the evaluation of difficult biliary strictures. Gastrointest Endosc. 2013;78(6):868-874.</Citation>
        </Reference>
        <Reference>
          <Citation>Barner-Rasmussen N, Pukkala E, Jussila A, Farkkila M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020;55(1):74-81.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
